Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2011-12-01 Director's Dealing
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Response to ASX query 3 pages 71.5KB
Director's Dealing Classification · 95% confidence The document is a letter from the company secretary of Biotron Limited responding to a compliance query from ASX Compliance Pty Limited regarding a late filing of Appendix 3Y, which is a Change of Director's Interest Notice. The content focuses on director shareholding disclosures and compliance with ASX listing rules 3.19A and 3.19B. There is no financial data, earnings information, or report attached. The document is a regulatory compliance communication about director share transactions and disclosure obligations. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 6239 characters, sufficient for a detailed compliance letter. Therefore, the classification is DIRS with high confidence.
2011-12-01 English
Change of Director`s Interest Notice 3 pages 52.5KB
Director's Dealing Classification · 100% confidence The document is a formal notice addressed to the ASX Limited regarding a change in a director's interest in the company's securities. It references Listing Rule 3.19A and includes an Appendix 3Y form, which is specifically used for reporting changes in directors' shareholdings. The content details the number of shares held before and after the change, the nature of the transactions, and confirms compliance with regulatory requirements. There is no financial report, earnings data, or management discussion present. The document is clearly a report of personal share transactions by a company director, fitting the definition of Director's Dealing.
2011-11-29 English
Option Expiry Notice 4 pages 60.1KB
Capital/Financing Update Classification · 95% confidence The document is an Option Expiry Notice from Biotron Limited, dated 30 November 2011, addressed to option holders regarding the expiry of options on 30 December 2011. It includes detailed instructions on exercising options, payment methods, and an update on the company's clinical trial activities. The document is primarily an announcement and notice related to the expiry and exercise of options, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis. The content fits the category of a Capital/Financing Update (CAP) because it relates to the company's capital structure changes through option exercise and expiry. The document length (10,420 characters) supports it being a full notice rather than a brief announcement or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2011-11-29 English
Appendix 3B 8 pages 65.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a New Issue Announcement and Application for Quotation of Additional Securities submitted to the ASX (Australian Securities Exchange). It details the issuance of fully paid ordinary shares, the number of securities issued, issue price, and other related information. The document is a regulatory announcement about a capital raising event and the application for quotation of these new shares on the exchange. It is not a financial report, earnings release, or management discussion. It is a formal announcement of a share issue and capital change. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not merely a brief announcement but a full Appendix 3B form, supporting a high confidence in classification.
2011-11-24 English
Presentation to Annual General Meeting 19 pages 260.5KB
AGM Information Classification · 95% confidence The document is a PowerPoint presentation intended to be delivered at the Annual General Meeting (AGM) of Biotron Limited on 22 November 2011. It contains forward-looking statements, clinical trial updates, capital raising information, and strategic plans. The text explicitly states it is a presentation to the AGM and includes detailed business and financial information typical of an investor presentation. The document is not a full annual report, audit report, or earnings release, but rather a presentation material for the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (over 10,000 characters) supports that it is a full presentation rather than a brief announcement or regulatory filing.
2011-11-21 English
Results of Meeting 2 pages 26.3KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document contains detailed voting results from an Annual General Meeting (AGM), including resolutions passed and proxy vote counts. It also includes the Notice of Annual General Meeting with agenda items and resolutions to be voted on. The content is focused on the outcomes of shareholder votes at the AGM rather than the full AGM materials or presentations. The document length is short (2648 characters) and it is primarily reporting the voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2011-11-21 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.